16:34 EDT ProMIS Neurosciences (PMN) files to sell 28.23M common shares for holders
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN:
- Promising Outlook for ProMIS Neurosciences’ PMN310 in Alzheimer’s Treatment with Buy Rating and $3.00 Price Target
- ProMIS Neurosciences Advances Alzheimer’s Trial to Final Phase
- ProMIS receives DSMB approval to advance final dose escalation cohort
- ProMIS Neurosciences Announces At The Market Offering
- ProMIS Neurosciences: Advancements in Alzheimer’s Treatment and Strong Financial Positioning Drive Buy Rating